Evidence map›Paper›PMID 34943408›Full record

ReviewDiagnostics (Basel, Switzerland)2021

INSM1, a Novel Biomarker for Detection of Neuroendocrine Neoplasms: Cytopathologists' View.

Zahra Maleki, Akash Nadella, Mohnish Nadella, Gopi Patel, Shivni Patel, Ivana Kholová

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. New Concepts of Regeneration and Renewal of Adrenal Chromaffin Cells.International journal of molecular sciences · 2025
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. [Whipple's triad with high and low insulin levels].Innere Medizin (Heidelberg, Germany) · 2023
    Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Zahra MalekiDivision of Cytopathology, Department of Pathology, The Johns Hopkins Hospital, The Johns Hopkins Medical Institution, Baltimore, MD 21218, USA.
Akash NadellaDepartment of Pathology, Johns Hopkins University, Baltimore, MD 21218, USA.
Mohnish NadellaDepartment of Pathology, Johns Hopkins University, Baltimore, MD 21218, USA.
Gopi PatelDepartment of Pathology, Johns Hopkins University, Baltimore, MD 21218, USA.
Shivni PatelDepartment of Pathology, Johns Hopkins University, Baltimore, MD 21218, USA.ORCID 0000-0003-3002-0136
Ivana KholováDepartment of Pathology, Fimlab Laboratories, Tampere, Faculty of Medicine and Health Technology, Tampere University, 33100 Tampere, Finland.ORCID 0000-0003-4089-0450
Johns Hopkins University · USTampere University · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInsulinoma-associated protein 1 (INSM1) has been considered as a novel immunostain for neuroendocrine tumors (NETs) and is hypothesized to be more reliable than first-generation NET biomarkers, such as CGA (chromogranin A), SYP (synaptophysin) and CD56 (neural cell adhesion molecule). In this review, we summarize existing literature on INSM1's reliability as an immunostain for detection of various NETs, its results in comparison to first-generation NET biomarkers, and its expression in both non-NETs and benign tissues/cells on cytology specimens (cell blocks/smears).

Indexed as

carcinoidcytologyINSM-1 immunostainingmedullary thyroid carcinomaneuroendocrine tumorpancreatic neuroendocrine tumorpulmonary neuroendocrine neoplasms

Identifiers

PMID34943408
PMCPMC8700458
OpenAlexW3215233808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.